Platinum Investment Management LTD Intellia Therapeutics, Inc. Transaction History

Platinum Investment Management LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$132.37 - $176.78 $2.8 Million - $3.74 Million	-21,157 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$60.88 - $161.91 $978,219 - $2.6 Million	-16,068 Reduced 43.16%	21,157 $3.43 Million
Q1 2021 May 13, 2021	SELL	$46.59 - $83.68 $360,513 - $647,515	-7,738 Reduced 17.21%	37,225 $2.99 Million
Q4 2020 Feb 12, 2021	SELL	$18.83 - $63.53 $377,880 - $1.27 Million	-20,068 Reduced 30.86%	44,963 $2.45 Million
Q3 2020 Nov 13, 2020	SELL	$17.47 - $24.93 $326,793 - $466,340	-18,706 Reduced 22.34%	65,031 $1.29 Million
Q1 2020 May 15, 2020	BUY	$9.44 - $15.58 $165,832 - $273,693	17,567 Added 26.55%	83,737 $1.02 Million
Q3 2019 Nov 14, 2019	SELL	$13.07 - $18.51 $714,719 - $1.01 Million	-54,684 Reduced 45.25%	66,170 $883,000
Q1 2019 May 15, 2019	BUY	$12.79 - $17.62 $177,947 - $245,147	13,913 Added 13.01%	120,854 $2.06 Million
Q4 2018 Feb 14, 2019	BUY	$11.39 - $27.13 $591,607 - $1.41 Million	51,941 Added 94.44%	106,941 $1.46 Million
Q1 2018 May 15, 2018	BUY	$19.43 - $34.95 $1.07 Million - $1.92 Million	55,000 New	55,000 $1.16 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $916M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Platinum Investment Management LTD, based on Form 13F filings with the SEC.

Stay updated on Platinum Investment Management LTD with notifications on news.